{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05020730",
            "orgStudyIdInfo": {
                "id": "PTM-001-01"
            },
            "organization": {
                "fullName": "Phoenicis Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa",
            "officialTitle": "A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial With a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa",
            "therapeuticArea": [
                "Other"
            ],
            "study": "trial-to-determine-the-immunomodulatory-activity-of-ptm-in-patients-with-hidradenitis-suppurativa"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-18",
            "studyFirstSubmitQcDate": "2021-08-24",
            "studyFirstPostDateStruct": {
                "date": "2021-08-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-10-24",
            "lastUpdatePostDateStruct": {
                "date": "2022-10-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Phoenicis Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Study PTM-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12 week open-label extension to examine the immunomodulatory activity of PTM-001 in participants with Hidradenitis Suppurativa (HS). Participants will be randomized to receive PTM-001 (400 mg) or matching placebo every day for 12 weeks after which all participants will receive open-label PTM-001 400 mg daily for an additional 12 weeks. Randomization will be stratified by Hurley Stage."
        },
        "conditionsModule": {
            "conditions": [
                "Hidradenitis Suppurativa"
            ],
            "keywords": [
                "Hidradenitis Suppurativa",
                "HS",
                "Inflammatory skin disease",
                "Humira",
                "P2X7",
                "IL-1\u03b2"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Patients will be randomized to receive PTM-001 (400 mg) or matching placebo every day for 12 weeks after which all patients will receive open-label PTM-001 400 mg daily for an additional 12 weeks",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "PTM-001 400 mg daily for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: PTM-001"
                    ]
                },
                {
                    "label": "Placebo daily for 12 weeks",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PTM-001",
                    "description": "PTM-001 (400 mg) every day for 12 weeks",
                    "armGroupLabels": [
                        "PTM-001 400 mg daily for 12 weeks"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Matching placebo every day for 12 weeks",
                    "armGroupLabels": [
                        "Placebo daily for 12 weeks"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Effect of PTM-001 on IL-1\u03b2 protein levels in lesional skin biopsies",
                    "timeFrame": "Baseline to Week 12"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Demonstrate a change in IL-1\u237a, IL-23p19, IL-17A, IL-5, IL-6, TNF\u237a, HBD-2 protein levels in lesional skin biopsies",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Demonstrate a change in IL-1\u03b2, IL-1\u237a, IL-23p19, IL-17A, IL-5, IL-6, TNF\u237a, HBD-2 mRNA expression in lesional skin biopsies",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Demonstrate a change in IL-1\u03b2, IL-1\u237a, IL-23p19, IL-17A, IL-5, IL-6, TNF\u237a, HBD-2 protein levels in serum",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Demonstrate a change in serum amyloid A levels",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in Pain, as measured using a 10-point numerical rating scale, 1 through 10, with 10 being the worst.",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in Quality of Life using Dermatology Life Quality Index (DLQI)",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in clinical status using the Hurley Staging",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in clinical status using the International Hidradenitis Suppurative Severity Score System (IHS4)",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in clinical status using the Hidradenitis Suppurative Clinical Response (HiSCR)",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in clinical status using the Hidradenitis Suppurative Physician Global Assessment (HS-PGA)",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in clinical status using the Hidradenitis Suppurative Area and Severity Index-Revised (HASI-R)",
                    "timeFrame": "Baseline to Week 12"
                },
                {
                    "measure": "Change in abscesses and inflammatory nodules count (AN count)",
                    "timeFrame": "Baseline to Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Had onset of symptoms consistent with HS at least 6 months prior to Screening.\n* Has had active HS for at least 2 months.\n* Has \u2265 5 HS abscesses or inflammatory nodules at Screening.\n* Agrees to maintain baseline wound care and antibiotic therapy, including oral antibiotics, for the duration of the trial.\n* Agrees to use contraception\n\nExclusion Criteria:\n\n* Has other skin disease or condition that can interfere with HS assessment.\n* Has a positive test for TB, HIV, hepatitis B and/or hepatitis C at Screening.\n* Has a history of retinopathy or known clinically significant cardiovascular or hematologic conditions.\n* Has taken any biologic drug within 3 serum half-lives. A list of potential biologics and their half-lives\n* Has started oral antibiotics within 28 days of Study Day 1.\n* Has, within 2 weeks prior to Day 1, received a medication prohibited based on cytochrome P450 (CYP3A4) interaction\n* Has such extensive disease that, in the opinion of the Investigator, it is difficult to discriminate between active lesions and scarring.\n* Has more than 15 active tunnels at Screening.\n* Is pregnant, nursing or considering becoming pregnant.\n* Has a history of malignancy except non-melanoma skin cancer or cervical carcinoma in situ.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ramsey Johnson, MSM",
                    "role": "CONTACT",
                    "phone": "978-726-1478",
                    "email": "ramsey@phoenicistx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Phoenicis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Redwood City",
                    "state": "California",
                    "zip": "94063",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "(978) 726-1478",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.48522,
                        "lon": -122.23635
                    }
                },
                {
                    "facility": "Phoenicis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Worcester",
                    "state": "Massachusetts",
                    "zip": "01655",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "(978) 726-1478",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.26259,
                        "lon": -71.80229
                    }
                },
                {
                    "facility": "Phoenicis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "(978) 726-1478",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017497",
                    "term": "Hidradenitis Suppurativa"
                },
                {
                    "id": "D000016575",
                    "term": "Hidradenitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000013543",
                    "term": "Sweat Gland Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000017192",
                    "term": "Skin Diseases, Bacterial"
                },
                {
                    "id": "D000001424",
                    "term": "Bacterial Infections"
                },
                {
                    "id": "D000001423",
                    "term": "Bacterial Infections and Mycoses"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000012874",
                    "term": "Skin Diseases, Infectious"
                },
                {
                    "id": "D000013492",
                    "term": "Suppuration"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19762",
                    "name": "Hidradenitis Suppurativa",
                    "asFound": "Hidradenitis Suppurativa",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18964",
                    "name": "Hidradenitis",
                    "asFound": "Hidradenitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16323",
                    "name": "Sweat Gland Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19500",
                    "name": "Skin Diseases, Bacterial",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4722",
                    "name": "Bacterial Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M12136",
                    "name": "Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M4721",
                    "name": "Bacterial Infections and Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M15677",
                    "name": "Skin Diseases, Infectious",
                    "relevance": "LOW"
                },
                {
                    "id": "M16273",
                    "name": "Suppuration",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M326",
                    "name": "Adalimumab",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}